Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT
NCT06334367
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
40
Enrollment
OTHER_GOV
Sponsor class
Conditions
GVHD
Interventions
DRUG:
CD25 treatment
DRUG:
low-dose ATG
Sponsor
Wang Xin